|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||7.86 / 19.90|
Levi & Korsinsky announces it has commenced an investigation of Momenta Pharmaceuticals, Inc.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABMD, ABX, AEM, BGG, BIIB, HBM, HTBI, KALU, MNTA, NEWM, NQ, SNE, VMI, VPG, WMT, XCRA Downgrades: CGNX, DAKT, EXAC, FSLR, HOLI, PFLT Initiations: AGR Read on to get TheStreet Quant Ratings' detailed report:
Here are Wednesday's top research calls, including downgrades for Discovery, First Solar and Momenta, and an upgrade for VF Corp.
Gilead (finally!) has acquired something from Sarepta, even if it is quite small.
The drug company saw its stock climb 3% Tuesday on news that it can move ahead with generic Copaxone.
Mylan, Momenta Pharmaceuticals and Seres Therapeutics were among the biotech stock movers in premarket trading on Tuesday.
Four of Teva's Orange-Book listed patents ruled invalid due to obviousness
Investors in Momenta Pharmaceuticals Inc saw new options become available this week, for the February 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNTA options chain for the new February 2017 contracts and identified the following put contract of particular interest.
In recent trading, shares of Momenta Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $15.50, changing hands for $15.70/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
President-elect Trump's vague healthcare policy has put the $3 trillion industry on edge.
Data show M230's ability to block immune complex-mediated damage and robust efficacy in preclinical
-- Advancement of M834 to clinical-stage development represents important milestone in the Momenta/Mylan biosimilar portfolio --
Advancement of M834 to clinical-stage development represents important milestone in the Momenta/Mylan biosimilar portfolio